Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020.
CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Exp Hematol. 2019..
The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. Cell Rep. 2019;27(1):238-254.e6.
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019..
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2019;35(2):333-335.
Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3(24):4326-4335..
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell. 2018;34(5):724-740.e4.